Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.59
(-2.34%)
CAD 4.59
(-2.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.89 Million CAD | -63.01% |
| 2022 | -22.63 Million CAD | -8.44% |
| 2021 | -20.87 Million CAD | -829.41% |
| 2020 | -2.24 Million CAD | 63.46% |
| 2019 | -6.14 Million CAD | 57.06% |
| 2018 | -14.31 Million CAD | -187.97% |
| 2017 | -4.97 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.96 Million CAD | 27.38% |
| 2024 Q1 | -9.02 Million CAD | -42.17% |
| 2023 Q3 | -8.62 Million CAD | -15.84% |
| 2023 FY | -37.88 Million CAD | -67.4% |
| 2023 Q4 | -6.34 Million CAD | 26.38% |
| 2023 Q2 | -7.44 Million CAD | -53.58% |
| 2023 Q1 | -4.84 Million CAD | 43.47% |
| 2022 Q2 | -6.02 Million CAD | -79.62% |
| 2022 Q4 | -8.57 Million CAD | -83.4% |
| 2022 FY | -22.63 Million CAD | -8.44% |
| 2022 Q1 | -3.35 Million CAD | 1.57% |
| 2022 Q3 | -4.67 Million CAD | 22.44% |
| 2021 Q2 | -5.28 Million CAD | 25.85% |
| 2021 Q4 | -3.4 Million CAD | 32.4% |
| 2021 Q1 | -7.13 Million CAD | -11410.6% |
| 2021 FY | -20.87 Million CAD | -829.41% |
| 2021 Q3 | -5.04 Million CAD | 4.63% |
| 2020 Q2 | -676.12 Thousand CAD | 32.06% |
| 2020 FY | -2.24 Million CAD | 63.46% |
| 2020 Q4 | -61.95 Thousand CAD | 89.78% |
| 2020 Q3 | -606.34 Thousand CAD | 10.32% |
| 2020 Q1 | -995.11 Thousand CAD | -200.83% |
| 2019 Q3 | -1.56 Million CAD | 0.0% |
| 2019 FY | -6.14 Million CAD | 57.06% |
| 2019 Q4 | -330.79 Thousand CAD | 78.89% |
| 2018 FY | -14.31 Million CAD | -187.97% |
| 2017 FY | -4.97 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -358.334% |
| Helix BioPharma Corp. | -9.37 Million CAD | -293.733% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -1248.352% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | -87.646% |
| Satellos Bioscience Inc. | -15.46 Million CAD | -138.613% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | -9.191% |
| Sernova Corp. | -41.13 Million CAD | 10.294% |